CBD has shown promise in treating alcohol use disorder, reducing withdrawal symptoms and curbing relapse in rodents during a clinical trial. Curaleaf stock surged nearly 10% on the news of this potential health benefit of CBD. Researchers at the University of California, San Diego found that rodents given synthetic CBD had milder withdrawal symptoms and lower relapse risks. This study, partially funded by the National Institute on Alcohol Abuse and Alcoholism, could lead to a revival of interest in CBD. However, before investing in Curaleaf, consider other top stock picks recommended by The Motley Fool’s Stock Advisor team.

Read more at Nasdaq: Why Curaleaf Stock Wafted Almost 10% Higher Today